Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jan;25(1):81–87. doi: 10.1111/j.1365-2125.1988.tb03285.x

N-acetylation phenotyping with dapsone in a mainland Chinese population.

Y Horai 1, H H Zhou 1, L M Zhang 1, T Ishizaki 1
PMCID: PMC1386618  PMID: 3370194

Abstract

1 The N-acetylation of dapsone (DDS) was studied in 108 unrelated Chinese subjects residing in the mainland of China. 2 The frequency of slow acetylators determined using the plasma monoacetyldapsone to DDS ratio (MADDS/DDS, slow acetylators less than 0.30 and rapid acetylators greater than 0.35) at 3 h after an oral dose of DDS (100 mg) was 13.0% (14 of the 108 subjects) with a 95% confidence interval of 7.9 to 20.6%. 3 The mean plasma concentration of MADDS was about three times lower in the slow than in the rapid acetylators and there was a highly significant correlation (rs = 0.886, P less than 0.001) between plasma MADDS concentration and acetylation ratio. 4 Urinary acetylation ratios (MADDS/DDS) and cumulative urinary excretion of MADDS were significantly (P less than 0.001) lower in slow acetylators compared with rapid acetylators. In addition, there was a significant relationship (rs = 0.510 to 0.718, P less than 0.001) between plasma and urinary acetylation ratios. However, the distribution of the urinary acetylation ratio was not bimodal. 5 The urinary acetylation ratio after an oral dose of DDS is not a discriminative index for determining acetylation phenotype.

Full text

PDF
85

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad R. A., Rogers H. J. Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method. Eur J Clin Pharmacol. 1980 Feb;17(2):129–133. doi: 10.1007/BF00562621. [DOI] [PubMed] [Google Scholar]
  2. Carr K., Oates J. A., Nies A. S., Woosley R. L. Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol. 1978 Nov;6(5):421–427. doi: 10.1111/j.1365-2125.1978.tb04606.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clark D. W. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs. 1985 Apr;29(4):342–375. doi: 10.2165/00003495-198529040-00003. [DOI] [PubMed] [Google Scholar]
  4. Drayer D. E., Reidenberg M. M. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther. 1977 Sep;22(3):251–258. doi: 10.1002/cpt1977223251. [DOI] [PubMed] [Google Scholar]
  5. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ellard G. A., Gammon P. T. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. Br J Clin Pharmacol. 1977 Feb;4(1):5–14. doi: 10.1111/j.1365-2125.1977.tb00659.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Evans D. A. Ethnic differences in reactions to drugs and xenobiotics. Acetylation. Prog Clin Biol Res. 1986;214:209–242. [PubMed] [Google Scholar]
  8. Gelber R., Peters J. H., Gordon G. R., Glazko A. J., Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225–238. doi: 10.1002/cpt1971122part1225. [DOI] [PubMed] [Google Scholar]
  9. Hanson A., Melander A., Wåhlin-Boll E. Acetylator phenotyping: a comparison of the isoniazid and dapsone tests. Eur J Clin Pharmacol. 1981;20(3):233–234. doi: 10.1007/BF00544604. [DOI] [PubMed] [Google Scholar]
  10. Horai Y., Ishizaki T. Rapid and sensitive liquid chromatographic method for the determination of dapsone and monoacetyldapsone in plasma and urine. J Chromatogr. 1985 Dec 13;345(2):447–452. doi: 10.1016/0378-4347(85)80187-0. [DOI] [PubMed] [Google Scholar]
  11. Horai Y., Ishizaki T., Sasaki T., Koya G., Matsuyama K., Iguchi S. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects. Br J Clin Pharmacol. 1982 Mar;13(3):361–374. doi: 10.1111/j.1365-2125.1982.tb01387.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ishizaki T., Eichelbaum M., Horai Y., Hashimoto K., Chiba K., Dengler H. J. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol. 1987 Apr;23(4):482–485. doi: 10.1111/j.1365-2125.1987.tb03080.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Iyun A. O., Lennard M. S., Tucker G. T., Woods H. F. Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther. 1986 Oct;40(4):387–394. doi: 10.1038/clpt.1986.195. [DOI] [PubMed] [Google Scholar]
  14. Kukongviriyapan V., Lulitanond V., Areejitranusorn C., Kongyingyose B., Laupattarakasem P. N-acetyltransferase polymorphism in Thailand. Hum Hered. 1984;34(4):246–249. doi: 10.1159/000153471. [DOI] [PubMed] [Google Scholar]
  15. Lunde P. K., Frislid K., Hansteen V. Disease and acetylation polymorphism. Clin Pharmacokinet. 1977 May-Jun;2(3):182–197. doi: 10.2165/00003088-197702030-00003. [DOI] [PubMed] [Google Scholar]
  16. Peters J. H., Murray J. F., Jr, Gordon G. R., Gelber R. H. Dapsone in saliva and plasma of man. Pharmacology. 1981;22(3):162–171. doi: 10.1159/000137486. [DOI] [PubMed] [Google Scholar]
  17. Philip P. A., Roberts M. S., Rogers H. J. A rapid method for determination of acetylation phenotype using dapsone. Br J Clin Pharmacol. 1984 Apr;17(4):465–469. doi: 10.1111/j.1365-2125.1984.tb02373.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Reidenberg M. M., Drayer D. E., Levy M., Warner H. Polymorphic acetylation procainamide in man. Clin Pharmacol Ther. 1975 Jun;17(6):722–730. doi: 10.1002/cpt1975176722. [DOI] [PubMed] [Google Scholar]
  19. SUNAHARA S., URANO M., LIN H. T., CHEG T. J., JARUMILINDA A. FURTHER OBSERVATIONS ON TRIMODALITY OF FREQUENCY DISTRIBUTION CURVE OF BIOLOGICALLY ACTIVE ISONIAZID BLOOD LEVELS AND "CLINE" INFREQUENCIES OF ALLELES CONTROLLING ISONIAZID INACTIVATION. Acta Tuberc Pneumol Scand. 1963;43:181–195. [PubMed] [Google Scholar]
  20. SUNAHARA S., URANOM, OGAWAM Genetical and geographic studies on isoniazid inactivation. Science. 1961 Nov 10;134(3489):1530–1531. doi: 10.1126/science.134.3489.1530. [DOI] [PubMed] [Google Scholar]
  21. Weber W. W. Acetylation pharmacogenetics: experimental models for human toxicity. Fed Proc. 1984 May 15;43(8):2332–2337. [PubMed] [Google Scholar]
  22. Weber W. W., Hein D. W., Litwin A., Lower G. M., Jr Relationship of acetylator status to isoniazid toxicity, lupus erythematosus, and bladder cancer. Fed Proc. 1983 Nov;42(14):3086–3097. [PubMed] [Google Scholar]
  23. Weber W. W., Hein D. W. N-acetylation pharmacogenetics. Pharmacol Rev. 1985 Mar;37(1):25–79. [PubMed] [Google Scholar]
  24. Zuidema J., Hilbers-Modderman E. S., Merkus F. W. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet. 1986 Jul-Aug;11(4):299–315. doi: 10.2165/00003088-198611040-00003. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES